Article Text
Statistics from Altmetric.com
I read with great interest the paper by Scarsi et al. 1 The authors examined the effect of colchicine (1 mg/day) in patients with COVID-19 by setting standard of care (hydroxychloroquine, and/or intravenous dexamethasone, and/or lopinavir/ritonavir).1 The adjusted HR (95% CI) of colchicine for mortality was 0.151 (0.062–0.368). In contrast, older age, worse PaO2/FiO2 and higher serum levels of ferritin at entry were no risk factors of mortality. The authors recommended controlled clinical trials to verify efficacy and safety, and I …
Footnotes
Contributors The author presented the recent information on the association between colchicine and COVID-19.
Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; internally peer reviewed.